Skip to content
About GRP
Why Choose Us
Leadership
Brochure
Careers
Countries
Canada’s Health Canada
United States’ FDA
Brazil
Mexico’s COFEPRIS
Europe’s EMA
Australia
China
Japan’s PMDA
Korea’s Ministry of Food and Drug Safety (MFDS)
Taiwan’s Food and Drug Administration (TFDA)
Singapore’s HSA
India’s CDSCO
North America
Canada
United States of America
Latin AMerica
Brazil
Mexico
Europe
European Union
Australia
Australia
Asia
China
Japan
South Korea
Taiwan
Singapore
India
Services
Medical Devices
Authorized Local Agent
Regulatory Intelligence
Regulatory Strategy
Regulatory Affairs
Product Registration
Medical Writing
Health Authority Consultation
Clinical
Pharmaceuticals
Authorized Local Agent
Regulatory Intelligence
Regulatory Strategy
Regulatory Affairs
Product Registration
Regulatory Operations
Health Authority Consultation
Nutraceuticals / Food Supplements
Authorized Local Agent
Regulatory Intelligence
Regulatory Affairs
Regulatory Strategy
Verification of Nutrient Claims
Verification of Health Claims
Cosmetics & Personal Care Products
Authorized Local Agent
Regulatory Intelligence
Regulatory Affairs
Regulatory Strategy
Cosmetic Packaging and Labeling Review
Product Classification and Formulation Review
Pharmacovigilance
Overview
GRP Pharmacoviglance Services
Quality
Preparation for FDA Inspections
GMP Mockup Quality Audits
ISO 13485 Quality Audits
GCP Audits
cGTP Audits
GAP Analysis Audits
Foreign Manufacture Accreditation (FMA)
QA SOPs Development
Resource Center
Blog
Market Access Special Programs
Press Releases
White Papers
Case Studies
Videos
Presentations
Brochure
RI Platform
Japan Regulatory Intelligence (RI)
China (NMPA) Regulatory Intelligence
Brazil
Mexico Regulatory Intelligence (RI)
USA Regulatory Intelligence (RI)
Japan
Health Authority
Medical Device
Pharmaceuticals
Clinical Trials
Cosmetics
Food Supplements
China
Health Authority
Medical Device
Pharmaceuticals
Clinical Trials
Cosmetics
Food Supplements
Brazil
Health Authority
Medical Device
Pharmaceuticals
Clinical Trials
Cosmetics
Food Supplements
Mexico
Health Authority
Medical Device
Pharmaceuticals
Clinical Trials
Cosmetics
Food Supplements
USA
Medical Device
Pharmaceuticals
Clinical Trials
Cosmetics
Food Supplements
Contact Us
X
About GRP
Why Choose Us
Leadership
Brochure
Careers
Countries
Canada’s Health Canada
United States’ FDA
Brazil
Mexico’s COFEPRIS
Europe’s EMA
Australia
China
Japan’s PMDA
Korea’s Ministry of Food and Drug Safety (MFDS)
Taiwan’s Food and Drug Administration (TFDA)
Singapore’s HSA
India’s CDSCO
Services
Resource Center
Blog
Market Access Special Programs
Press Releases
White Papers
Case Studies
Videos
Presentations
Brochure
RI Platform
Japan Regulatory Intelligence (RI)
China (NMPA) Regulatory Intelligence
Brazil
Mexico Regulatory Intelligence (RI)
USA Regulatory Intelligence (RI)
Contact Us
Menu
About GRP
Why Choose Us
Leadership
Brochure
Careers
Countries
Canada’s Health Canada
United States’ FDA
Brazil
Mexico’s COFEPRIS
Europe’s EMA
Australia
China
Japan’s PMDA
Korea’s Ministry of Food and Drug Safety (MFDS)
Taiwan’s Food and Drug Administration (TFDA)
Singapore’s HSA
India’s CDSCO
Services
Resource Center
Blog
Market Access Special Programs
Press Releases
White Papers
Case Studies
Videos
Presentations
Brochure
RI Platform
Japan Regulatory Intelligence (RI)
China (NMPA) Regulatory Intelligence
Brazil
Mexico Regulatory Intelligence (RI)
USA Regulatory Intelligence (RI)
Contact Us
Case Study 047: Waiver of FDA Fee for NDA in USA
December 27, 2022
FDA Fee Waiver
USA
New Drug Application (NDA)
LEARN MORE
GRP Can support your Regulatory, Clinical, Quality & Safety Needs
Contact Us !
Stay updated on the Latest Regulatory Information
SUBSCRIBE
Linkedin
Twitter
Youtube
Back to all Case Studies
For more details contact GRP at info@globalregulatorypartners.com
Search
Search
Contact Us!
